Cytokinetics, Incorporated (CYTK)
$
32.3
+0.22 (0.68%)
Key metrics
Financial statements
Free cash flow per share
-3.4543
Market cap
3.8 Billion
Price to sales ratio
199.3557
Debt to equity
-2.9693
Current ratio
5.9856
Income quality
0.6469
Average inventory
0
ROE
8.0126
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The cost of revenue for the company is $9,531,000.00 showcasing its production and operational expenses. With a gross profit ratio of 0.48 the company reflects the efficiency of its production and sales operations. In terms of profitability, the company reported an income before tax of -$589,526,000.00 which highlights its pre-tax profitability. The total costs and expenses for the company amount to $554,722,000.00 reflecting its overall spending. Additionally, the EBITDA ratio is -26.71 underscoring the company's operational efficiency. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility, including omecamtiv mecarbil, a novel cardiac myosin activator currently in Phase III clinical trials for heart failure, as well as reldesemtiv, a skeletal muscle troponin activator undergoing Phase III trials for amyotrophic lateral sclerosis and spinal muscular atrophy. Other developments include CK-136, a cardiac troponin activator in Phase I trials, aficamten, a cardiac myosin inhibitor in Phase III trials for symptomatic obstructive hypertrophic cardiomyopathy, and CK-3772271, a small molecule cardiac myosin inhibitor currently in Phase I trials. The company, incorporated in 1997 and headquartered in South San Francisco, California, has a strategic alliance with Astellas Pharma Inc. The stock is affordable at $32.30 making it suitable for budget-conscious investors. Moreover, the stock has a high average trading volume of 2,093,507.00 which indicates strong liquidity. With a mid-range market capitalization of $3,857,492,100.00 the company is considered a steady performer. As a key player in the Biotechnology industry, Cytokinetics contributes significantly to the overall market landscape, while it belongs to the Healthcare sector, driving innovation and growth. This combination of financial stability and progressive R&D positions Cytokinetics as an attractive consideration for potential investors aiming for meaningful engagement in the biopharmaceutical field.
Is Cytokinetics, Incorporated (CYTK) a good investment?
Investing in Cytokinetics, Incorporated (CYTK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Cytokinetics, Incorporated (CYTK)'s stock forecast?
Analysts predict Cytokinetics, Incorporated stock to fluctuate between $29.31 (low) and $61.38 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cytokinetics, Incorporated's market capitalization?
As of 2025-06-06, Cytokinetics, Incorporated's market cap is $3,857,492,100, based on 119,427,000 outstanding shares.
How does Cytokinetics, Incorporated compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Cytokinetics, Incorporated has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cytokinetics, Incorporated (CYTK) stock?
To buy Cytokinetics, Incorporated (CYTK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CYTK. Place an order (Market, Limit, etc.).
What is the best time to invest in Cytokinetics, Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Cytokinetics, Incorporated stock ever split?
Cytokinetics, Incorporated's last stock split was 1:6 on 2013-06-25.
How did Cytokinetics, Incorporated perform in the last earnings report?
Revenue: $18,474,000 | EPS: -$5.26 | Growth: -3.49%.
Where can I find Cytokinetics, Incorporated's investor relations reports?
Visit https://www.cytokinetics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cytokinetics, Incorporated?
You can explore historical data from here
What is the all-time high and low for Cytokinetics, Incorporated stock?
All-time high: $110.25 (2024-01-08) | All-time low: $17.72 (2021-07-14).
What are the key trends affecting Cytokinetics, Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.
See all news
